Flavopiridol in Treating Patients With Recurrent Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 1997

Primary Completion Date

April 30, 2000

Conditions
Lymphoma
Interventions
DRUG

alvocidib

Trial Locations (10)

46617

Michiana Hematology/Oncology P.C., South Bend

60068

Lutheran General Hospital, Park Ridge

60201

Evanston Northwestern Health Care, Evanston

60612

Clinical Sciences Building, Chicago

60637

University of Chicago Cancer Research Center, Chicago

60640

Louis A. Weiss Memorial Hospital, Chicago

61602

Oncology/Hematology Associates of Central Illinois, P.C., Peoria

62526

Cancer Care Specialists of Central Illinois, S.C., Decatur

62701

Central Illinois Hematology Oncology Center, Springfield

46885-5099

Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00003039 - Flavopiridol in Treating Patients With Recurrent Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma | Biotech Hunter | Biotech Hunter